Premium
Medroxyprogesterone acetate in non‐metastatic gestational trophoblastic disease
Author(s) -
GOLDBERG GARY L.,
CLOETE KOBUS,
BLOCH BASIL,
WISWEDEL KLAUS,
ALTARAS MARCO M.
Publication year - 1987
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1987.tb02246.x
Subject(s) - medroxyprogesterone acetate , medicine , gestational trophoblastic disease , medroxyprogesterone , obstetrics , gynecology , hormone , incidence (geometry) , trophoblastic neoplasm , trophoblastic tumor , pregnancy , gestation , physics , biology , optics , genetics
Summary. The effect of medroxyprogesterone acetate (MPA: Depo‐Provera, Upjohn) as a contraceptive agent was assessed in 45 patients with non‐metastatic gestational trophoblastic disease and compared with 13 patients using hormonal and 26 patients using non‐hormonal methods of contraception. In the whole group of 84 patients 18 (21.4%) required chemotherapy. There was no statistically significant difference in the incidence of persistent trophoblastic disease between MPA (9/45) and the oral contraceptive group (2/13) and MPA and the non‐hormonal contraceptive groups (7/26).